15 Sep 2016 --- "We want to be a predator, not prey," says Olivier Rigaud, the chief executive of Naturex, which has reported revenues up 2.7 percent to €208m ($234m) in the six months to June 30 and is now sizing up further acquisitions. Operating income was up nearly 50 percent to €18.6m ($21m), helped by strong organic growth in emerging markets, although new stringent rules in the US nutraceutical market, such as stricter regulations on DNA testing on botanicals, hurt its performance across North America.
